Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

ADHD

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults With Attention-Deficit/Hyperactivity Disorder
Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.
10/26/2023
Growth Trajectories of Youth with Attention-Deficit/Hyperactivity Disorder Treated with Delayed-Release/Extended-Release Methylphenidate: A Pilot Database Analysis of Real-World Data
DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...
10/26/2023
Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study
Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...
10/26/2023
A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).
Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...
10/26/2023
A Randomized, Five-Way Crossover Study to Evaluate Bioequivalence of the Dextroamphetamine Transdermal System (d-ATS) at Five Application Sites in Healthy Adults
In a pivotal study, d-ATS applied to the hip met primary and secondary efficacy endpoints for ADHD in children and adolescents. In this open-label crossover study, healthy adults were ran...
10/26/2023
A Thorough QT Trial Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization
Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...
10/26/2023
52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...
10/26/2023
.st0 {fill: #000;}
Dr Greg Mattingly
Videos
Understanding the Stimulant Shortage
09/05/2023

With Greg Mattingly, MD

With Greg Mattingly, MD
Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.
Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.
Dr Mattingly explains the...
09/05/2023
Psych Congress Network
Viloxazine Extended-Release Capsules (Qelbree®) for Adults with Attention-Deficit/Hyperactivity Disorder: Evaluating the Potential Impact of Caffeine Exposure on Safety Profile
Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...
01/19/2023
A Retrospective Real-World Analysis Demonstrating the Value of Azstarys for Patients With Attention-Deficit Hyperactivity Disorder
Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the...
01/19/2023
Serdexmethylphenidate/Dexmethylphenidate for Children With Attention-Deficit Hyperactivity Disorder: Reduction in Disorder Severity From a Laboratory Classroom Study
Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (S...
01/19/2023
The Impact of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function in Adults with Attention-Deficit/Hyperactivity Disorder
Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...
01/19/2023
Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...
01/19/2023
A Model-Based Pharmacokinetic Comparison of Delayed-Release/Extended-Release Methylphenidate to Extended-Release Methylphenidates with Immediate-Release Supplementation
Abstract: Purpose: Immediate-release methylphenidate (IR MPH) is sometimes dosed in the afternoon to extend the duration of effect of a morning-dosed extended-release (ER) MPH for attenti...
01/19/2023
Effect Size and NNT of the Dextroamphetamine Transdermal System (d-ATS) for ADHD in Children and Adolescents: Post-Hoc Analysis of a Pivotal Study
Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. This post-hoc...
01/19/2023
Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder
Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Method...
01/19/2023
Interpreting Improvements in Emotional Lability with Delayed-Release and Extended-Release Methylphenidate Treatment in Children with Attention-Deficit/Hyperactivity Disorder
Abstract: Purpose: Emotional lability (EL) is commonly seen in individuals with attention-deficit/hyperactivity disorder (ADHD). A post hoc analysis found that DR/ER-MPH (formerly HLD200)...
01/19/2023

Advertisement

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

Advertisement

ECS
November 8 ⁠–⁠ November 10
December 9 ⁠–⁠ December 11
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
May 28 ⁠–⁠ May 31
See Full Calendar

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use